HER-2 overexpression + HR positive

HER2-low status was associated with worse OS in breast cancer patients with certain negative prognostic factors compared with HER2-zero status. Additionally, HER2-low1+ and HER2-low2+/ISH(-) subgroups predominantly exhibited HR+ status.

P2, N=63, Completed, City of Hope Medical Center | Active, not recruiting --> Completed

In our study, breast tumors with neuroendocrine features exhibited a luminal immunophenotype and did not demonstrate a clearly distinct clinical behavior compared with conventional hormone receptor positive breast cancer. Neuroendocrine differentiation may therefore represent a morphological feature within the luminal spectrum rather than a distinct biological entity.

This multicenter retrospective study included 290 female patients diagnosed with HER2-positive early or locally advanced breast cancer treated with neoadjuvant trastuzumab and pertuzumab-based regimens (anthracycline-based [AC-THP] or non-anthracycline [TCHP]) across six centers. pCR remains the strongest surrogate for survival, neutralizing initial risk factors. These findings support using quantitative biomarker thresholds for personalization and reinforce the efficacy of non-anthracycline regimens.

Our findings indicate that COL1A2 is associated with reduced chemotherapy sensitivity in HR+/HER2- breast cancer and may serve as a candidate biomarker to guide neoadjuvant taxane selection. This study provides a novel theoretical basis for optimizing neoadjuvant chemotherapy regimens in patients with advanced HR+/HER2- breast cancer.

BNETs represent a biologically distinct subset of breast cancers with favorable prognostic features and a consistent luminal-like phenotype. However, evidence on optimal treatment remains limited. Further large-scale, prospective studies are needed to define clinical management and validate molecular findings.

Furthermore, its diagnostic capability using exosomes derived from HER2+/HR- cells achieves a LOD of 1.2 × 103 particles/mL, demonstrating strong clinical applicability. The proposed aptamer-integrated electrochemical biosensing platform is a noninvasive and point-of-care approach for the early diagnosis of HER2+/HR- subtype, providing insights into molecularly targeted BC diagnostics.

HER2-low HR+ RecurIndex-DR low risk patients may not benefit from adjuvant chemotherapy. RecurIndex may help explore prognostic stratification and may guide potential chemotherapy de-escalation in HER2-low early BC, laying groundwork for future ADC use.

P=N/A, N=28, Completed, Centre Antoine Lacassagne | N=47 --> 28 | Active, not recruiting --> Completed

These findings indicate that metformin synergistically enhances the antitumor activity of alpelisib in HER2-positive breast cancer by inhibiting oncogenic signaling and stemness pathways. Beyond its metabolic benefit in mitigating hyperglycemia, metformin may potentiate PI3K-targeted therapies, supporting further preclinical and clinical evaluation of this combination strategy.

P1/2, N=67, Active, not recruiting, Immunitas Therapeutics | Recruiting --> Active, not recruiting | N=151 --> 67 | Trial completion date: Apr 2025 --> Jan 2026 | Trial primary completion date: Apr 2025 --> Jan 2026

P2, N=162, Active, not recruiting, UNICANCER | Recruiting --> Active, not recruiting